Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialCOHEN, Calvin J; ANDRADE-VILLANUEVA, Jaime; VANVEGGEL, Simon et al.Lancet (British edition). 2011, Vol 378, Num 9787, pp 229-237, issn 0140-6736, 9 p.Article

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trialCAHN, Pedro; ANDRADE-VILLANUEVA, Jaime; ROLON, Maria José et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 7, pp 572-580, issn 1473-3099, 9 p.Article

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients : 48 week efficacy and safety results of the CASTLE study. CommentaryTORTI, Carlo; MOLINA, Jean-Michel; RANG YANG et al.Lancet (British edition). 2008, Vol 372, Num 9639, issn 0140-6736, 604-606, 646-655 [13 p.]Article

Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 WeeksZAJDENVERG, Roberto; PODSADECKI, Thomas J; BADAL-FAESEN, Sharlaa et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 54, Num 2, pp 143-151, issn 1525-4135, 9 p.Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityMOYLE, Graeme J; ANDRADE-VILLANUEVA, Jaime; BALOGH, Agnes et al.Antiviral therapy (London). 2012, Vol 17, Num 4, pp 689-700, issn 1359-6535, 12 p.Article

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyMOLINA, Jean-Michel; LAMARCA, Anthony; ANDRADE-VILLANUEVA, Jaime et al.Lancet. Infectious diseases (print). 2012, Vol 12, Num 1, pp 27-35, issn 1473-3099, 9 p.Article

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral―naive HIV-1 patients: the ARTEN TrialSORIANO, Vicente; ARASTEH, Keikawus; DOMINGO, Pere et al.Antiviral therapy (London). 2011, Vol 16, Num 3, pp 339-348, issn 1359-6535, 10 p.Article

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE StudyMOLINA, Jean-Michel; ANDRADE-VILLANUEVA, Jaime; WIRTZ, Victoria et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 3, pp 323-332, issn 1525-4135, 10 p.Article

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48ORTIZ, Roberto; DEJESUS, Edwin; VANGENEUGDEN, Tony et al.AIDS (London). 2008, Vol 22, Num 12, pp 1389-1397, issn 0269-9370, 9 p.Article

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1―Infected Patients: Week 48 ResultsGALLANT, Joel E; KOENIG, Ellen; YAPEI LIU et al.The Journal of infectious diseases. 2013, Vol 208, Num 1, pp 32-39, issn 0022-1899, 8 p.Article

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsGATHE, Joseph; ANDRADE-VILLANUEVA, Jaime; NGUYEN, Thuy et al.Antiviral therapy (London). 2011, Vol 16, Num 5, pp 759-769, issn 1359-6535, 11 p.Article

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialERON, Joseph; ROCKSTROH, Jürgen K; NELSON, Mark et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 12, pp 907-915, issn 1473-3099, 9 p.Article

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyCAHN, Pedro; POZNIAK, Anton L; HAGINS, Debbie et al.Lancet (British edition). 2013, Vol 382, Num 9893, pp 700-708, issn 0140-6736, 9 p.Article